Despite impressive innovations in medicine, most advanced-stage cancers still carry a grim prognosis.

Developing more effective treatments requires a deeper understanding of the cellular processes that drive the formation and growth of common cancers.

Growth factor receptors are well-established drivers of many cancers, and many modern therapies target these receptors effectively.

However, cancers in most patients eventually become resistant to existing drugs.

By identifying new cellular components required for growth factor signaling, researchers have uncovered a new class of therapeutic targets.

A new Penn Nursing study suggests that the specific sedatives used during critical illness in early childhood may have long-term implications for a child’s neurocognitive development. Martha A.Q. Curley, PhD, RN, FAAN, Professor in the Department of Family and Community Health, and the Ruth M. Colket Endowed Chair in Pediatric Nursing at Children’s Hospital of Philadelphia. co-led the study with R. Scott Watson, MD, from Seattle Children’s Hospital.